Pipeline news

• Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

  16 June 2021

  

  Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that it has achieved a milestone associated with the development of AT-527 and expects to receive a related payment under its license agreement with Roche of $50 million. Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19. Atea retains rights to commercialize AT-527 in the United States and Roche has the exclusive right to commercialize AT-527 outside of the United States. 

• Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs

  15 June 2021

  

  Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences.

• Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

  15 June 2021

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD).

• Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for Xipere™ (triamcinolone acetonide suprachoroidal injectable suspension)

  02 June 2021

  

  Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch&Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside”), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™1 (triamcinolone acetonide suprachoroidal injectable suspension). 

• binx health Raises $104 Million in Series E Financing

  27 May 2021

  

  binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, today announced the closing of a Series E financing of $104 million. 

• OCON Healthcare Develops New Women’s Health Devices

  24 May 2021

  

  OCON Healthcare, an Israeli FemTech startup, manufactures and commercializes innovative 3D intrauterine devices (IUD) for women who wish to conceive based on its patented IUB (Intra-Uterine Ball) platform.The company has a woman as its chair, Dr. Anula Jayasuriya.

• Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

  20 May 2021

  

  Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership.

• binx health Submits Request for Emergency Use Authorization for First CRISPR-based Point-of-care Test for COVID-19

  18 May 2021

  

  binx health announced the submission of an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for the first CLIA-waived CRISPR-based point-of-care (POC) test for COVID-19. binx io is already the first CLIA-waived platform for the molecular detection of chlamydia and gonorrhea in about 30 minutes. binx has now adapted the single-use cartridge for analysis of RNA-based targets, pairing the high performance of Sherlock Biosciences’ proprietary CRISPR technology with binx’s rapid and sensitive proprietary electrochemical detection to create a powerful tool to help combat COVID-19.

• Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

  17 May 2021

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for first quarter ended March 31, 2021.

• Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

  17 May 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the first quarter ended March 31, 2021.